The irAEs associated with the combination therapy included colitis, hepatitis, pneumonitis, and endocrinopathies such as hypophysitis, which occur at substantially higher rates compared to those seen with PD-1 inhibitors alone. Here, PDCD1 is linked to hypophysitis.